614 related articles for article (PubMed ID: 17513464)
1. Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress.
Workman P; Burrows F; Neckers L; Rosen N
Ann N Y Acad Sci; 2007 Oct; 1113():202-16. PubMed ID: 17513464
[TBL] [Abstract][Full Text] [Related]
2. Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone.
Workman P
Cancer Lett; 2004 Apr; 206(2):149-57. PubMed ID: 15013520
[TBL] [Abstract][Full Text] [Related]
3. The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones.
Workman P
Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S45-56. PubMed ID: 12819933
[TBL] [Abstract][Full Text] [Related]
4. Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors.
Powers MV; Workman P
Endocr Relat Cancer; 2006 Dec; 13 Suppl 1():S125-35. PubMed ID: 17259553
[TBL] [Abstract][Full Text] [Related]
5. High-throughput screening assay for inhibitors of heat-shock protein 90 ATPase activity.
Rowlands MG; Newbatt YM; Prodromou C; Pearl LH; Workman P; Aherne W
Anal Biochem; 2004 Apr; 327(2):176-83. PubMed ID: 15051534
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of cancer invasion and metastasis by targeting the molecular chaperone heat-shock protein 90.
Koga F; Kihara K; Neckers L
Anticancer Res; 2009 Mar; 29(3):797-807. PubMed ID: 19414312
[TBL] [Abstract][Full Text] [Related]
7. Heat-shock protein 90 (Hsp90) as a molecular target for therapy of gastrointestinal cancer.
Moser C; Lang SA; Stoeltzing O
Anticancer Res; 2009 Jun; 29(6):2031-42. PubMed ID: 19528462
[TBL] [Abstract][Full Text] [Related]
8. Targeting Hsp90 for the treatment of cancer.
Drysdale MJ; Brough PA; Massey A; Jensen MR; Schoepfer J
Curr Opin Drug Discov Devel; 2006 Jul; 9(4):483-95. PubMed ID: 16889231
[TBL] [Abstract][Full Text] [Related]
9. Geldanamycin and its anti-cancer activities.
Fukuyo Y; Hunt CR; Horikoshi N
Cancer Lett; 2010 Apr; 290(1):24-35. PubMed ID: 19850405
[TBL] [Abstract][Full Text] [Related]
10. Heat shock protein 90: a unique chemotherapeutic target.
Cullinan SB; Whitesell L
Semin Oncol; 2006 Aug; 33(4):457-65. PubMed ID: 16890800
[TBL] [Abstract][Full Text] [Related]
11. Extracellular heat shock protein 90: a role for a molecular chaperone in cell motility and cancer metastasis.
Tsutsumi S; Neckers L
Cancer Sci; 2007 Oct; 98(10):1536-9. PubMed ID: 17645779
[TBL] [Abstract][Full Text] [Related]
12. Hsp90: the vulnerable chaperone.
Chiosis G; Vilenchik M; Kim J; Solit D
Drug Discov Today; 2004 Oct; 9(20):881-8. PubMed ID: 15475321
[TBL] [Abstract][Full Text] [Related]
13. Synergistic antipancreatic tumor effect by simultaneously targeting hypoxic cancer cells with HSP90 inhibitor and glycolysis inhibitor.
Cao X; Bloomston M; Zhang T; Frankel WL; Jia G; Wang B; Hall NC; Koch RM; Cheng H; Knopp MV; Sun D
Clin Cancer Res; 2008 Mar; 14(6):1831-9. PubMed ID: 18347186
[TBL] [Abstract][Full Text] [Related]
14. Small-molecule targeting of heat shock protein 90 chaperone function: rational identification of a new anticancer lead.
Meli M; Pennati M; Curto M; Daidone MG; Plescia J; Toba S; Altieri DC; Zaffaroni N; Colombo G
J Med Chem; 2006 Dec; 49(26):7721-30. PubMed ID: 17181154
[TBL] [Abstract][Full Text] [Related]
15. Heat shock protein-90 inhibitors: a chronicle from geldanamycin to today's agents.
Chiosis G; Caldas Lopes E; Solit D
Curr Opin Investig Drugs; 2006 Jun; 7(6):534-41. PubMed ID: 16784024
[TBL] [Abstract][Full Text] [Related]
16. Anti-myeloma activity of the novel 2-aminothienopyrimidine Hsp90 inhibitor NVP-BEP800.
Stühmer T; Chatterjee M; Grella E; Seggewiss R; Langer C; Müller S; Schoepfer J; Garcia-Echeverria C; Quadt C; Jensen MR; Einsele H; Bargou RC
Br J Haematol; 2009 Nov; 147(3):319-27. PubMed ID: 19686236
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo.
Schwock J; Pham NA; Cao MP; Hedley DW
Cancer Chemother Pharmacol; 2008 Apr; 61(4):669-81. PubMed ID: 17579866
[TBL] [Abstract][Full Text] [Related]
18. Hsp90 inhibitors: clinical development and future opportunities in oncology therapy.
Gao Z; Garcia-Echeverria C; Jensen MR
Curr Opin Drug Discov Devel; 2010 Mar; 13(2):193-202. PubMed ID: 20205053
[TBL] [Abstract][Full Text] [Related]
19. Discovery and development of Hsp90 inhibitors: a promising pathway for cancer therapy.
Porter JR; Fritz CC; Depew KM
Curr Opin Chem Biol; 2010 Jun; 14(3):412-20. PubMed ID: 20409745
[TBL] [Abstract][Full Text] [Related]
20. Purine-scaffold Hsp90 inhibitors.
Chiosis G; Tao H
IDrugs; 2006 Nov; 9(11):778-82. PubMed ID: 17096299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
